NASDAQ:MNKD MannKind (MNKD) Stock Price, News & Analysis $5.72 +0.06 (+0.97%) As of 01:15 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About MannKind Stock (NASDAQ:MNKD) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get MannKind alerts:Sign Up Key Stats Today's Range$5.68▼$5.8650-Day Range$5.42▼$7.0252-Week Range$3.47▼$7.63Volume805,406 shsAverage Volume1.87 million shsMarket Capitalization$1.58 billionP/E Ratio81.50Dividend YieldN/APrice Target$9.21Consensus RatingBuy Company OverviewMannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.Read More… MannKind Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks57th Percentile Overall ScoreMNKD MarketRank™: MannKind scored higher than 57% of companies evaluated by MarketBeat, and ranked 478th out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingBuy Consensus RatingMannKind has received a consensus rating of Buy. The company's average rating score is 3.13, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageMannKind has only been the subject of 3 research reports in the past 90 days.Read more about MannKind's stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth130.00% Earnings GrowthEarnings for MannKind are expected to grow by 130.00% in the coming year, from $0.10 to $0.23 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of MannKind is 81.36, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 23.35.Price to Earnings Ratio vs. SectorThe P/E ratio of MannKind is 81.36, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 25.93.Read more about MannKind's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted10.24% of the float of MannKind has been sold short.Short Interest Ratio / Days to CoverMannKind has a short interest ratio ("days to cover") of 10.3, which indicates bearish sentiment.Change versus previous monthShort interest in MannKind has recently decreased by 1.16%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMannKind does not currently pay a dividend.Dividend GrowthMannKind does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted10.24% of the float of MannKind has been sold short.Short Interest Ratio / Days to CoverMannKind has a short interest ratio ("days to cover") of 10.3, which indicates bearish sentiment.Change versus previous monthShort interest in MannKind has recently decreased by 1.16%, indicating that investor sentiment is improving. News and Social Media1.9 / 5News Sentiment0.42 News SentimentMannKind has a news sentiment score of 0.42. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for MannKind this week, compared to 4 articles on an average week.Search Interest9 people have searched for MNKD on MarketBeat in the last 30 days. This is an increase of 125% compared to the previous 30 days.MarketBeat FollowsOnly 6 people have added MannKind to their MarketBeat watchlist in the last 30 days. This is a decrease of -14% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, MannKind insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $465,323.00 in company stock.Percentage Held by InsidersOnly 3.00% of the stock of MannKind is held by insiders.Percentage Held by Institutions49.55% of the stock of MannKind is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about MannKind's insider trading history. Receive MNKD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MannKind and its competitors with MarketBeat's FREE daily newsletter. Email Address MNKD Stock News HeadlinesMannKind Corp (MNKD) Announces Upcoming Release of 2024 Financial ResultsFebruary 20 at 8:30 PM | gurufocus.comMannKind Corporation to Hold 2024 Fourth Quarter and Full Year Financial Results Conference Call on February 26, 2025February 19 at 4:05 PM | globenewswire.comA deadly mistake in my prediction…I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again. February 21, 2025 | Porter & Company (Ad)MannKind (NASDAQ:MNKD) Coverage Initiated at WedbushFebruary 12, 2025 | americanbankingnews.comMannKind initiated with an Outperform at WedbushFebruary 10, 2025 | markets.businessinsider.comMannKind to Present at Upcoming Investor ConferencesFebruary 6, 2025 | uk.finance.yahoo.comMannKind Corp (MNKD) Announces Participation in Key Investor ConferencesFebruary 6, 2025 | gurufocus.comTop Picks 2025- MannKind MNKDFebruary 4, 2025 | finance.yahoo.comSee More Headlines MNKD Stock Analysis - Frequently Asked Questions How have MNKD shares performed this year? MannKind's stock was trading at $6.43 at the beginning of the year. Since then, MNKD stock has decreased by 11.3% and is now trading at $5.7050. View the best growth stocks for 2025 here. How were MannKind's earnings last quarter? MannKind Co. (NASDAQ:MNKD) announced its earnings results on Thursday, November, 7th. The biopharmaceutical company reported $0.04 EPS for the quarter, hitting analysts' consensus estimates of $0.04. The biopharmaceutical company earned $70.08 million during the quarter, compared to analysts' expectations of $77.27 million. MannKind had a net margin of 8.07% and a negative trailing twelve-month return on equity of 17.74%. Who are MannKind's major shareholders? MannKind's top institutional investors include Vanguard Group Inc. (5.82%), Nitorum Capital L.P. (3.17%), Geode Capital Management LLC (2.31%) and Arrowstreet Capital Limited Partnership (1.77%). Insiders that own company stock include Michael Castagna, Steven B Binder, Stuart A Tross, David Thomson, Alejandro Galindo and Anthony C Hooper. View institutional ownership trends. How do I buy shares of MannKind? Shares of MNKD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of MannKind own? Based on aggregate information from My MarketBeat watchlists, some other companies that MannKind investors own include Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), Bausch Health Companies (BHC), Intel (INTC) and Netflix (NFLX). Company Calendar Last Earnings11/07/2024Today2/21/2025Next Earnings (Estimated)5/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:MNKD CUSIP56400P20 CIK899460 Webwww.mannkindcorp.com Phone(818) 661-5000Fax661-775-2081Employees400Year Founded1991Price Target and Rating Average Stock Price Target$9.21 High Stock Price Target$12.00 Low Stock Price Target$6.50 Potential Upside/Downside+58.7%Consensus RatingBuy Rating Score (0-4)3.13 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)$0.07 Trailing P/E Ratio83.07 Forward P/E Ratio58.05 P/E GrowthN/ANet Income$-11,940,000.00 Net Margins8.07% Pretax Margin9.37% Return on Equity-17.74% Return on Assets8.68% Debt Debt-to-Equity RatioN/A Current Ratio4.54 Quick Ratio4.17 Sales & Book Value Annual Sales$198.96 million Price / Sales8.05 Cash FlowN/A Price / Cash FlowN/A Book Value($0.91) per share Price / Book-6.38Miscellaneous Outstanding Shares275,780,000Free Float267,505,000Market Cap$1.60 billion OptionableOptionable Beta1.28 Social Links Beginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (NASDAQ:MNKD) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MannKind Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share MannKind With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.